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Abstract
Aim
Metabolic risk factors are poorly documented for the first generation of young adults who
have lived with HIV since childhood. We compared their metabolic profile with that of adults
of same age from the general population.
Methods
We conducted a cross-sectional analysis of data from two populations: (1) COVERTE
(ANRS-CO19), a French national cohort of 18 to 30-year-old patients HIV-infected since
childhood, and (2) ENNS, a national cross-sectional population-based household survey on
nutrition. Body mass index (BMI), blood pressure, waist circumference, fasting glucose, tri-
glycerides, and HDL-, LDL- and total cholesterol were measured in both studies. Direct stan-
dardization on overweight and education level and logistic regression were used to compare
the prevalence of metabolic abnormalities between the two populations.
Results
Data from 268 patients from COVERTE and 245 subjects from ENNS were analyzed.
Tobacco use was similar in both groups. HIV-infected patients had increased mean waist-
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to-hip ratio and triglycerides to HDL-cholesterol ratio and decreased mean HDL-cholesterol
as compared to their counterparts from the general population in both genders. In HIV-
infected patients, metabolic syndrome was identified in 13.2% of men (95% confidence
interval [CI]: 7.1–19.2) and 10.4% (95% CI: 5.4–15.3) of women versus 10.6% (95%CI: 1.5–
19.7) and 1.7% (95%CI: 0–4.1) in subjects from the general population, respectively.
Conclusion
Young adults infected with HIV since childhood had a higher prevalence of dyslipidemia and
metabolically detrimental fat distribution than adults of same age of the general population,
supporting close monitoring for cardiometabolic diseases.
Introduction
Cardiovascular diseases are an important cause of non-AIDS-related morbidity and mortality
in HIV-infected patients. They are the third cause of death of HIV-infected patients after
AIDS events and hepatic diseases [1]. In a previously studied French cohort, the age- and sex-
standardized risk of myocardial infarction in HIV-infected patients relative to the general pop-
ulation was 1.5 [95% confidence interval (CI) 1.3–1.7] overall, 1.4 (95% CI 1.3–1.6) in men,
and 2.7 (95% CI 1.8–3.9) in women [2]. Myocardial infarctions occur at a younger age in HIV-
infected patients, suggesting premature aging of the cardiovascular system [3]. Multiple syner-
gistic risk factors, either traditional (tobacco use, components of the metabolic syndrome, age)
or HIV-related (exposure to antiretroviral therapy [ART], immune/inflammatory alterations,
lipodystrophy syndrome, decreased insulin sensitivity), may contribute to accelerated athero-
sclerosis in HIV-infected patients [4, 5]. The prevalence of diabetes in European HIV-infected
patients has approached that of the general population in recent years, including in France [6–
8], but dyslipidemia and insulin resistance associated with ART remain significant risk factors
[9]. HIV-infected adults (aged 35–44 years) treated with a protease inhibitor-based ART regi-
men had lower mean high-density lipoprotein (HDL) cholesterol levels, higher mean waist-to-
hip ratio, and higher mean triglyceride levels than persons of the same age from the French
general population [10]. They also exhibited a higher prevalence of smoking with an overall
greater predicted risk of coronary heart disease.
Few studies have examined the cardiovascular risks in the first generation of young adults
living with HIV since birth or childhood. This is an emerging population, due to the improved
prognosis of HIV infection treated with powerful ART. The cardiometabolic risk of HIV-
infected patients has significantly declined over the last few years, due to broadened treatment
indications, use of less toxic antiretrovirals, and better monitoring [11], but cardiometabolic
features in young adults HIV-infected during childhood may differ from those in individuals
infected during adulthood, for several reasons. These include the acquisition of HIV at a
young age, during a period of physiological immaturity and of a strong capacity of immune
regeneration through thymic activity; long exposure to HIV and long ART histories, with the
use of first generation drugs associated with the highest metabolic toxicity; and conversely, the
lack of exposure to behavioral risk factors, mainly tobacco use, during the first years of infec-
tion. In addition, fetal exposure to ART could increase the risk of cardiomyopathy [12].
A study conducted in the United States reported that coronary artery vessel wall thickness
was significantly higher in young adults aged 15–29 years who acquired HIV early in life than
in sex- and race-matched uninfected controls, indicating that this population is likely to
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present subclinical coronary vascular disease [13]. In addition, several studies conducted in
teenagers and young adults infected with HIV early in life (mostly through mother-to-child
transmission) showed a high prevalence of metabolic abnormalities, particularly dyslipidemia
and insulin resistance [14, 15, 16], as well as coronary artery abnormalities [17].. However,
these studies were of small sample size and/or did not include non HIV-infected control
groups.
The French national cohort of young adults living with HIV since childhood was designed
to study their living conditions and long-term prognosis. The availability of a national popula-
tion-based survey on nutrition provided the opportunity to compare their metabolic profile to
that of the adults of the same age living in France.
Patients and methods
Data sources
The ANRS COVERTE-CO19 (S1 and S2 Files) is an ongoing prospective cohort of adults diag-
nosed with HIV infection before 13 years of age (verified to be perinatally-acquired for almost
all patients), aged 18 to 25 years at inclusion, and enrolled in 88 sites (77 in metropolitan
France, six in French overseas cities, and five in Brussels and Liège, Belgium). One third of the
patients has been followed prospectively in the national cohort of HIV-infected children
(Enquête Pe´rinatale Franc¸aise, ANRS CO1) since birth. For the ANRS COVERTE-CO19
cohort, an annual standardized questionnaire is completed by the medical team to collect clini-
cal, therapeutic, and biological parameters from routine follow-up every six months, including
fasting glucose, triglycerides, and HDL-, LDL-, and total cholesterol; additional details on liv-
ing conditions and behaviors are collected through a self-administered questionnaire com-
pleted during each visit. Enrolment started in June 2010.
The ENNS (Etude Nationale Nutrition Sante´, S3 and S4 Files), a French national cross-sec-
tional population-based household survey, was conducted from February 2006 to July 2007.
The main objective was to describe nutritional status in metropolitan France. It was based on a
sampling design that provided a large representative sample of the population living in France
(excluding the island of Corsica and French overseas territories) [18]. The ENNS design con-
sisted of three-stage probability sampling with unequal inclusion probabilities stratified by
region and degree of urbanization. A subgroup of voluntary participants had clinical examina-
tions and provided biological samples. Post-stratification was performed to adjust for gender,
the national census data on age, level of education, presence of at least one child in the house-
hold, season of medical examination, and the availability of weight, height, and total choles-
terol measures. Data were collected in medical examination centers of the French National
Health Insurance System (Caisse Nationale d’Assurance Maladie des travailleurs salarie´s) or at
home.
COVERTE and ENNS received the approval of the Ethics Committee of the Ile de France
III (Hoˆpital Cochin no2264 and n˚2738, respectively). Participants in both studies provided
written informed consent.
Study population
The study included all participants from both studies, aged 18 to 30 years, living in France, and
not pregnant, except when information on the level of education, weight, height, or total cho-
lesterol were missing. For HIV-infected patients, we selected individuals for whom completed
self-questionnaire was available and biological parameters were collected within three months
from the latest visit.
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Variables studied
Metabolic outcomes. The body mass index (BMI) was calculated as the ratio of the weight
to the square of the height. Being overweight was defined as having a BMI�25. Metabolic
parameters were measured using standard procedures. The metabolic abnormalities studied
were those included in the Joint Interim Statement definition of metabolic syndrome [19]:
blood pressure�130/85 mmHg or the use of blood pressure-lowering medication; waist cir-
cumference�94 cm (men) or� 80 cm (women); fasting glucose�5.6 mmol/l or the use of
antidiabetic medication; triglycerides�1.7 mmol/l or the use of lipid-lowering medication;
HDL-cholesterol <1.03 mmol/l (men) or <1.29 mmol/l (women) or the use of specific medi-
cation. Metabolic syndrome was defined as having any three or more of the above metabolic
abnormalities. We also considered the thresholds of LDL-cholesterol� 3.4 mmol/L and total
cholesterol�5.16 mmol/L [20].
Main exposure. The main exposure was the HIV status: HIV-infected since childhood
(patients enrolled in COVERTE) or not HIV-infected (this was assumed, although systematic
HIV testing was not performed, subjects enrolled in ENNS representing the general popula-
tion living in France, without any subject having being exposed to ART).
The socio-demographic and behavioral characteristics collected in both studies were: gen-
der, age (18–24 vs 25–30 years), marital status (married or living with a partner vs. being sin-
gle), country of birth (metropolitan France vs. outside), employment status (working vs. not
working or student), education level (no qualification or middle school vs. high school
diploma or higher), and tobacco consumption (active vs. none or past), hormonal contracep-
tion, and psychotropic drug use.
The immuno-virological status and ART of HIV-infected patients were described by the
level of CD4 cell counts and viral load, the CDC clinical stage, the type of ART at study visit,
and the duration of exposure to any antiretroviral drug, including those reported to have meta-
bolic toxicity (zidovudine, stavudine, didanosine, protease inhibitors).
Statistical analysis
The analysis was conducted separately for men and women [21] on the database (S1 Dataset).
The mean values of metabolic parameters and the prevalence of abnormalities were estimated
with their 95% confidence intervals, according to the sampling design for ENNS. Crude num-
bers were used for both studies, but the percentages and means in the ENNS were weighted to
take into account unequal probabilities of inclusion and post-stratification. Moreover, esti-
mates in HIV-infected patients were standardized to adjust for the distribution of BMI (< 25
or� 25) and the education level (under or at least a high school diploma) of the 18 to 30-year-
old general population estimated from the ENNS survey, as these factors are strongly associ-
ated with metabolic status [21–23].
For HIV-specific parameters in COVERTE, the data for men and women were compared
using Pearson Chi-Square or Fischer exact tests. Quantitative variables were compared using
Kruskal-Wallis tests.
The association of the HIV status (as main exposure) with each metabolic parameter (as
dependent variable) was studied using linear regression models for continuous parameters and
logistic regression models for qualitative parameters. The models were systematically adjusted
for being overweight and education level in both genders. Further adjustment for the use of oral
contraceptives was performed in women as they are known to modify lipid metabolism [24].
A sensitivity analysis was conducted by excluding participants born outside France.
Statistical analyses were performed using the survey procedure of SAS 9.4. The threshold
for statistical significance was 0.05. No adjustment was used for multiple testing.
Young adult metabolic profile in HIV
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Results
Description of the study population
Between 2010 and 2016, the COVERTE cohort enrolled 386 patients infected with HIV since
childhood, of which 268 were included in the analyses (Fig 1), consisting of 47% men, with a
median age of 23 years [IQI: 21–26], of whom 55% completed high school. Their median BMI
was 22.3 [IQI: 20.1–24.8]. The data used for these analyses were collected between 2013 and
2015 for 227 patients (85%). Among the 427 adults aged 18–30 years enrolled in the ENNS in
Fig 1. Diagram for sample selection from the ANRS-COVERTE CO19 cohort and ENNS study.
https://doi.org/10.1371/journal.pone.0206745.g001
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2006–2007, 245 were included in the analyses, consisting of 42% men, with a median age of
22.5 years [IQI: 19–26], of whom 53.9% completed high school. Their median BMI was 22.8
[IQI: 20.2–25.3].
Several differences between HIV-infected patients and the ENNS general population of the
same gender remained after standardization based on education level and BMI (Table 1):
HIV-infected patients were less likely to be born in France, to live in couple and to be
employed or students, but tobacco use was similar; HIV-infected men were younger; and
HIV-infected women were less likely to take hormonal contraception.
At the time of the study visit, less than 1.5% of HIV-infected patients had never been treated
while, in the others, the median duration of ART was 19 years (Table 2). Approximately 90%
were currently on ART, two nucleoside reverse transcriptase inhibitors plus one protease
inhibitor being the most frequent regimen (40%). Twelve patients were still on zidovudine, 12
others on didanosine and one on stavudine at the time of data collection. The median CD4 cell
Table 1. Sociodemographic and behavioral characteristics of patients infected with HIV since childhood (ANRS COVERTE Cohort) and the French general popula-
tion (ENNS).
HIV-infected
men
(COVERTE:
(N = 126)
Men from general
population
(ENNS: N = 103)
HIV-infected
women
(COVERTE:
N = 142)
Women from general
population
(ENNS: N = 142)
% Stand. %� %�� % Stand. %� %��
Age 25–30 (ref 18–24) 32.5 32.0 42.6 32.4 33.3 35.5
Education level <high school diploma 50.8 54.7 54.7 39.4 36.7 36.7
Employment (10 missing
data)
(15 missing
data)
- Not working 30.2 33.9 8.1 37.8 36.5 18.2
- Student 25.8 23.7 30.9 31.5 33.2 41.2
- Working 44.0 42.4 61.0 30.7 30.3 40.6
Born in metropolitan France 68.2 67.8 94.7 70.4 70.1 94.8
Married/living with a partner (ref: Single Separated/divorced/
widowed)
(10 missing
data)
(14 missing
data)
17.2 16.9 32.1 24.2 23.5 41.4
Tobacco consumption (1 missing
data)
(1 missing
data)
- Every day 36.0 39.0 43.8 31.2 29.4 31.5
- Not every day 9.6 8.8 2.5 8.5 8.9 2.3
- In the past 12.8 12.9 12.0 14.2 14.9 14.2
- Never 41.6 39.3 41.8 46.1 46.8 52.0
Psychotropic drug use 3.2 3.5 3.3 4.9 4.8 3.2
Hormonal contraception NA NA NA 21.8 21.6 49.3
Body mass index (BMI)
- BMI < 18.5 7.9 6.9 0.5 9.8 9.6 10.2
- 18.5� BMI < 25 69.8 59.6 66.0 63.4 64.2 63.5
- BMI� 25 22.2 33.5 33.5 26.8 26.2 26.2
NA: not applicable; Stand.: standardized
� standardized prevalence for education level and BMI� 25
�� prevalence estimates for general population from ENNS, taking into account the sampling design (unequal inclusion probabilities) and post-stratification to adjust
each gender for the distribution of national census data on age, education, presence of at least one child in the household, season of medical examination, and the
availability of weight, height, and total cholesterol measures.
https://doi.org/10.1371/journal.pone.0206745.t001
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count was 554/microliter. Viral load was undetectable in 68% of patients, with a median of
3.19 log10 copies/mL, when detectable.
Six HIV-infected participants were treated with blood pressure-lowering drugs, two with
lipid-lowering drugs, and one with insulin for type 1 diabetes, whereas no participant in the
ENNS survey received any of these drugs.
Comparison of continuous metabolic parameters between HIV-infected
patients and the general population
After adjustment for education level and being overweight, HIV-infected patients of both gen-
ders differed from the general population for several metabolic parameters (Table 3). They had
higher waist-to-hip ratios than their counterparts from the general population, with higher
mean waist circumference in HIV-infected women. Regarding the lipid profile, HIV-infected
men showed a higher mean level of triglycerides and a lower mean level of HDL-cholesterol
than those from men from the general population. Although their LDL-cholesterol mean levels
were also lower, their total-to-HDL-cholesterol ratio tended to be higher than that from ENNS
men. HIV-infected women had higher mean systolic blood pressure than ENNS women, and
their mean total and HDL- and LDL- fractions of cholesterol were lower, with non signifi-
cantly different mean cholesterol total-to-HDL ratio and triglycerides levels. However, the
mean triglycerides-to-HDL cholesterol ratio was significantly higher in HIV-infected women.
In addition, after further adjustment for the use of hormonal contraception, mean total and
LDL-cholesterol were no longer different between HIV-infected and ENNS women (p = 0.176
and 0.120 respectively), whereas triglycerides levels were significantly higher (p = 0.021) and
HDL-cholesterol still tended to be lower (p = 0.069) in HIV-infected women.
Table 2. Comparison of antiretroviral treatment and immune-virological status, according to gender, of patients infected with HIV since childhood from the
ANRS CO19—COVERTE cohort.
Men (N = 126) Women (N = 142) p-value
N % M N % M
ART 0 0 0.181
- Never treated 2 1.6 1 0.7
- Treatment stopped 5 4.0 13 9.2
- On treatment 119 94.4 128 90.1
Type of ART regimen 0 1 0.556
- 2NRTI + 1NNRTI 25 20.1 37 26.4
- 2NRTI + PI 50 40.3 56 40.0
- II + others 32 25.8 28 20.0
- Other regimens 17 13.7 19 13.6
CDC Stage C 33 26.2 0 29 20.4 0 0.264
Undetectable plasma viral load 81 68.6 8 93 67.4 4 0.830
Median IQR Miss Median IQR Miss p-value
Viral load (log10 copies/mL), when detectable 3.64 2.11–4.25 8 3.03 2.01–4.39 4 0.589
CD4 (cells/microliter) 559 372–755 3 552 399–704 4 0.926
Time on ART (years) 18.8 12.4–22.1 0 18.9 12.1–21.8 1 0.806
Duration of exposure to ART with known metabolic toxicity� (years) 13.7 8.7–17.6 0 12.5 6.2–17.5 1 0.315
M: missing data; IQR: interquartile range; ART: antiretroviral therapy; NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase
inhibitors; PI: protease inhibitors; II: Integrase Inhibitors
� stavudine, didanosine, zidovudine, protease inhibitors
https://doi.org/10.1371/journal.pone.0206745.t002
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Comparison of metabolic abnormalities between HIV-infected patients
and the general population
An increased prevalence of several metabolic abnormalities was observed in COVERTE as
compared to the ENNS population, after standardization or adjustment for education level
and overweight.
HIV-infected men had a higher prevalence of elevated triglycerides and reduced HDL-cho-
lesterol levels than men of the general population (Table 4). The prevalence of metabolic syn-
drome did not differ significantly: 13.2% (95%CI 7.1–19.2) versus 10.6% (95%CI 1.5–19.7).
The most common cluster of abnormalities in participants with metabolic syndrome was ele-
vated triglycerides, reduced HDL-cholesterol and elevated blood pressure, found in six out of
14 HIV-infected individuals (43%) and in 36% of those from the general population.
HIV-infected women were more likely to have reduced HDL-cholesterol levels and a high
waist circumference, although they were less likely to have elevated total cholesterol than
women from the general population (Table 5). Their prevalence of metabolic syndrome was
significantly higher than in women from the general population: 10.4% (95%CI 5.4–15.3) ver-
sus 1.7% (95%CI 0–4.1), respectively, with an adjusted odds ratio of 9.9 (95%CI 1.9–51.3,
Table 3. Comparison of metabolic parameters of patients infected with HIV since childhood (COVERTE) versus the general population (ENNS), adjusted for being
overweight and education level, by linear regression.
HIV-infected men
(COVERTE:
N = 126)
Men from general
population (ENNS:
N = 103)
p-valueb HIV-infected women
(COVERTE:
N = 142)
Women from general
population (ENNS:
N = 142)
p-valuec p-valued
Mean 95%CI M Meana 95%CI M Mean 95%CI M Meana 95%CI M
BMI 22.6 21.9–
23.2
0 24.1 22.8–
25.4
0 0.026 22.9 22.2–
23.7
0 23.5 22.2–
24.9
0 0.409 0.241
Waist/Hip ratio 0.91 0.88–
0.93
22 0.86 0.85–
0.89
1 <10−4 0.86 0.83–
0.89
18 0.76 0.75–
0.78
1 <10−4 <10−4
Waist circumference (cm) 81.0 79.1–
82.9
22 84 80–88 1 0.419 80 77–83 17 76 73–78 1 0.002 0.016
Systolic blood pressure (mmHg) 122 120–125 10 120 117–124 0 0.088 116 113–119 10 109 107–112 0 <10−3 <10−4
Diastolic blood pressure (mmHg) 72 70–74 10 71 69–74 0 0.593 71 69–74 10 72 69–75 0 0.844 0.919
Fasting glucose
(mmol/L)
4.7 4.6–4.9 3 4.9 4.7–5.1 1 0.117 4.6 4.5–4.8 1 4.6 4.5–4.8 7 0.914 0.765
Triglycerides (mmol/L) 1.4 1.1–1.7 1 1.1 0.9–1.2 0 0.003 1.0 0.9–1.2 1 0.9 0.8–1.1 0 0.311 0.021
Total cholesterol, (mmol/L) 4.2 4.0–4.5 0 4.4 4.2–4.7 0 0.226 4.5 4.2–4.7 0 4.8 4.5–5.0 0 0.030 0.176
LDL-cholesterol, (mmol/L) 2.4 2.2–2.6 5 2.6 2.5–2.8 7 0.044 2.5 2.3–2.7 6 2.8 2.6–3.0 4 0.045 0.120
HDL-cholesterol, (mmol/L) 1.2 1.1–1.3 4 1.3 1.2–1.5 2 0.033 1.4 1.3–1.5 5 1.5 1.4–1.7 2 0.014 0.069
Non-HDL cholesterol, (mmol/L) 3.0 2.8–3.3 4 3.1 2.9–3.3 2 0.673 3.0 2.8–3.2 5 3.2 3.0–3.5 2 0.093 0.326
Total to HDL-cholesterol ratio 3.8 3.5–4.1 4 3.5 3.3–3.8 2 0.059 3.3 3.1–3.5 5 3.2 3.0–3.5 2 0.343 0.158
Triglycerides to HDL-cholesterol
ratio
1.4 1.1–1.8 5 0.9 0.7–1.1 2 0.003 0.8 0.7–0.9 6 0.6 0.6–0.7 2 0.008 0.0008
CI: Confidence Interval; M: missing data; BMI: Body Mass Index; HDL: high-density lipoprotein; LDL: low-density lipoprotein
a weighted to take into account unequal inclusion probabilities and post-stratification according to each gender for national census data on age, education, presence of at
least one child in the household, season of medical examination, and the availability of weight, height, and total cholesterol measures.
b Comparisons between HIV-infected men and men from the general population using linear regression adjusted for education level and being overweight (except for
BMI adjusted on education level only), taking into account sampling weights.
c Comparisons between HIV-infected women and women from the general population using linear regression adjusted for education level and being overweight (except
for BMI adjusted on education level only), taking into account sampling weights.
d Comparisons between HIV-infected women and women from the general population using linear regression adjusted for education level, being overweight and use of
oral contraceptives (except for BMI adjusted on education level only), taking into account sampling weights.
https://doi.org/10.1371/journal.pone.0206745.t003
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p = 0.006). After further adjustment for the use of oral contraceptives, odd-ratios related to
cholesterol levels were no longer significant although other results were not modified. The
most common cluster of abnormalities in the 15 HIV-infected women with metabolic
Table 4. Comparison of standardized prevalence of metabolic abnormalities in patients infected with HIV since childhood versus the general population for men
(COVERTE and ENNS studies) adjusted for being overweight and education level, by logistic regression.
HIV-infected men (COVERTE: n = 126) General population (ENNS:
n = 103)
Full logistic regression c
N % Stand.%a 95%CI M %b 95%CI M aOR 95%CI p-value
Overweight 28 22.2 22.2 14.9–29.5 0 33.5 21.2–45.8 0 0.6 0.3–1.1 0.106
Elevated blood pressure 41 35.0 36.1 27.2–45.0 9 31.0 19.2–42.8 0 1.6 0.8–3.3 0.193
Elevated waist circumference 12 11.4 16.2 9.0–23.4 21 14.3 5.2–23.3 1 1.5 0.4–5.2 0.497
Elevated fasting glucose 10 8.1 9.8 4.1–15.4 3 14.9 4.9–24.8 1 0.5 0.2–1.5 0.245
Elevated Triglycerides 28 22.4 22.9 15.3–30.5 1 9.5 1.0–18.0 0 4.4 1.7–11.7 0.003
Reduced HDL-cholesterol 43 34.9 36.3 27.4–45.2 3 23.7 11.0–36.5 2 2.1 0.9–5.0 0.083
Elevated LDL-cholesterol 13 10.7 11.5 5.5–17.4 4 12.4 6.0–18.7 7 0.9 0.4–2.0 0.735
Elevated total cholesterol 21 16.7 17.8 10.8–24.9 0 14.6 7.6–21.7 0 1.2 0.6–2.5 0.646
Metabolic syndrome 14 11.1 13.2 7.1–19.2 0 10.6 1.5–19.7 0 2.1 0.6–7.9 0.252
N: number; M: missing data; Stand.: standardized; aOR: adjusted Odds Ratio; CI: confidence interval; HDL: high-density lipoprotein; LDL: low-density lipoprotein
a standardized on education level and body mass index� 25 (except for overweight standardized on education level only)
b weighted to take into account unequal inclusion probabilities and post-stratification, according to each gender for national census data on age, education, presence of
at least one child in the household, season of medical examination, and the availability of weight, height, and total cholesterol measures
c using logistic regression adjusted for education level and being overweight (except for overweight adjusted on education level only), taking into account sampling
weights
https://doi.org/10.1371/journal.pone.0206745.t004
Table 5. Comparison of standardized prevalence of metabolic abnormalities in patients infected with HIV since childhood versus the general population for
women (COVERTE and ENNS), adjusted for being overweight and education level, by logistic regression.
HIV-infected women
(COVERTE: n = 142)
General population
(ENNS: n = 142)
Logistic regression #1c Logistic regression #2d
N % Stand.
%a
95%CI M %b 95%CI M aOR 95%CI p-value aOR 95%CI p-value
Overweight 36 25.3 25.4 18.2–32.5 0 26.2 16.3–36.2 0 0.9 0.4–1.8 0.831 0.8 0.3–1.7 0.601
Elevated blood pressure 29 22.0 21.1 14.2–28.1 10 13.6 5.8–21.5 0 1.8 0.8–4.1 0.129 1.9 0.8–4.8 0.153
Elevated waist circumference 51 40.8 40.3 33.5–47.2 17 23.9 14.3–33.6 2 5.9 2.2–15.6 0.0004 4.1 1.5–11.3 0.007
Elevated fasting glucose 7 5.0 5.7 1.8–9.6 1 1.2 0–3.6 7 ND ND ND ND ND ND
Elevated Triglycerides 13 9.2 8.8 4.3–13.2 1 7.9 1.2–14.7 0 1.1 0.3–3.5 0.862 2.0 0.6–6.1 0.198
Reduced HDL-cholesterol 55 40.1 39.0 31.0–47.0 5 24.9 15.0–34.8 2 2.0 1.0–4.0 0.034 1.8 0.8–3.8 0.138
Elevated LDL-cholesterol 19 14.0 14.1 8.1–20.1 6 16.8 8.7–25.0 4 0.8 0.3–1.7 0.557 1.0 0.4–2.2 0.988
Elevated total cholesterol 28 19.7 20.6 13.7–27.5 0 32.4 22.4–42.4 0 0.5 0.3–1.0 0.036 0.6 0.3–1.3 0.192
Metabolic syndrome 15 10.6 10.4 5.4–15.3 0 1.7 0–4.1 0 9.9 1.9–51.3 0.006 9.4 1.7–52.1 0.010
N: number; M: missing data; Stand.: standardized; aOR: adjusted Odds Ratio; CI: confidence interval; HDL: high-density lipoprotein; LDL: low-density lipoprotein
a standardized on education level and body mass index� 25 (except for overweight standardized on education level only)
b weighted to take into account unequal inclusion probabilities and post-stratification, according to each gender for national census data on age, education, presence of
at least one child in the household, season of medical examination, and the availability of weight, height, and total cholesterol measures
c using logistic regression adjusted for education level and being overweight (except for overweight adjusted on education level only), taking into account sampling
weights
d using logistic regression adjusted for education level, being overweight and use of oral contraceptives (except for overweight adjusted on education level only), taking
into account sampling weights
ND: not done because of too few events, the model was overfitted
https://doi.org/10.1371/journal.pone.0206745.t005
Young adult metabolic profile in HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0206745 November 8, 2018 9 / 15
syndrome was the combination of elevated triglycerides, reduced HDL-cholesterol and high
waist circumference (n = 8). The three women with metabolic syndrome from the general pop-
ulation presented with different clusters but all had a high waist circumference.
Sensitivity analyses
We conducted sensitivity analyses on the 412 subjects born in France (186 HIV-infected
patients, including 86 men, and 232 adults from the general population, including 94 men).
The results were quite similar to those obtained with the whole sample, except for a stronger
association with reduced HDL-cholesterol in HIV-infected men and a weaker association with
elevated total cholesterol in HIV-infected women (S1 Table).
Discussion
This study is the first to compare the metabolic parameters of young adults who acquired HIV
infection during childhood and controls of the same age from the general population. It points
to increased prevalence of cardiovascular and insulin resistance risk factors in HIV-infected
young subjects.
HIV-infected men had a lower BMI, but higher waist-to-hip ratio, higher triglycerides and
lower HDL-cholesterol levels (without showing increased LDL-cholesterol and non-HDL cho-
lesterol levels), than men of the same age in the general population. HIV-infected women had
a similar BMI as women of the same age from the general population, but a higher waist-to-
hip ratio associated with a larger waist circumference, and a higher systolic blood pressure.
They also had lower HDL-cholesterol levels without increased LDL-cholesterol and non-HDL
cholesterol levels. They had a higher mean triglycerides-to-HDL-cholesterol ratio and a higher
prevalence of the metabolic syndrome than women in the general population. In addition,
after further adjustment on the use of hormonal contraceptives, HIV-infected women showed
significantly higher triglycerides mean levels than those from the general population. These
results indicate that 18 to 30 year-olds with HIV infection display an atherogenic metabolic
profile, as compared to uninfected adults of the same age, similar to the findings in French
HIV-infected patients aged 35–44 years on protease inhibitors (APROCO study) [10]. How-
ever, in the latter study [10], the prevalence of smoking was much higher than in the general
population, partially explaining the higher cardiovascular risk. This was not the case in our
study, since tobacco consumption was similar between the two young populations.
Higher waist-to-hip ratio and serum triglycerides, associated with lower HDL-cholesterol
levels and higher triglycerides-to-HDL-cholesterol than in the general population, without dif-
ference in total or LDL cholesterol levels, are highly suggestive of a state of lower insulin sensi-
tivity in young subjects with HIV infection since childhood [25]. This metabolic profile was
also observed in HIV-infected adults in the APROCO study, exposed to first generation antire-
trovirals. Consistently, the young adult patients in our study have also been exposed for several
years to first generation ART regimens, including stavudine, zidovudine, didanosine, and pro-
tease inhibitors, such as ritonavir, known to alter lipid and glucose metabolism via adipocyte
dysfunction, inducing lipodystrophy insulin resistance, and dyslipidemia [26].
In the aforementioned study of HIV-infected French adults aged 35–44 years [10], meta-
bolic profiles were similar between men and women. In our study of young adults exposed to
HIV infection and ART since childhood, we observed distinct gender-specific metabolic fea-
tures with higher triglyceride levels in HIV-infected men, and larger waist circumference in
HIV-infected women, as compared to the general population of same age. This was not
explained by differences in antiretroviral exposure, clinical, or immuno-virological status at
the time of the study, but more likely by sex and gender-related factors. First, sex-based
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differences in immune activation have been described with a stronger interferon alpha
response in women [27] possibly contributing to metabolic disorders. Second, HIV infection
and antiretroviral treatments may interact with the estrogen/testosterone balance promoting
androgen exposure, resulting in an increase of visceral abdominal fat and lipid concentrations
[21, 28, 29], with more visible effects in women. Finally, differences in dietary and lifestyle hab-
its such as alcohol consumption, physical activity and psychological status [21], might also
explain an effect of gender on the associations between HIV and metabolic abnormalities.
Also, the risk of polycystic ovary syndrome, strongly associated with truncal adiposity in the
general population, was not reported to be increased in HIV-infected women with a mean age
of 41 years [30]. Further study of the ovarian and reproductive consequences of long-term
exposure to insulin resistance risk factors, as observed in young women with HIV infection
since childhood, would be of interest. Importantly, in addition to a proper screening of cardio-
metabolic diseases over time, the knowledge of increased prevalence of insulin resistance risk
factors in HIV-infected young women reinforces the need for a proper evaluation of their lipid
profile before prescribing a contraceptive pill.
Our study has several strengths. First, the availability of two national French studies that
collected metabolic and behavioral data for a similar number of eligible subjects at comparable
time periods made it possible to compare young HIV-infected patients with a general popula-
tion of the same gender and age distribution. Second, it was possible to standardize prevalence
and adjust models for BMI, strongly associated with metabolic syndrome, and education level,
associated with behavioral factors, nutritional habits, and metabolic syndrome in women in a
previous ENNS analysis [31]. We did not standardize for the distribution of age, as the 18 to
30-year age group appeared to be very homogenous, with a low global risk for metabolic
syndrome.
Our study has several limitations. First, the general population, as non-HIV-exposed group
was assumed rather than systematic HIV testing, which might have underestimated the
observed associations. The prevalence of HIV in France being about 4/1000 habitants, this bias
may be low [32]. Second, the current HIV-exposed group may not be representative of the
whole population of young adults infected with HIV since childhood in France which may
have introduced a selection bias. In particular, only one third of the patients from the Enquête
Pe´rinatale Franc¸aise, ANRS CO1 were still followed-up in COVERTE. We can hypothesize
that those who agreed to participate in COVERTE are those who were more concerned and
adherent with medical follow-up and presented a better health status, which might have also
underestimated the observed associations. Third, ethnic differences in the prevalence of meta-
bolic syndrome have been reported in the general population, particularly in the United States
[33], but ethnicity data were unavailable for our cohorts, and stratification by country of birth,
as a proxy for ethnicity, was not possible because of the small number of ENNS participants
born outside of France. We thus conducted a sensitivity analysis on men and women born in
metropolitan France, which confirmed our study results. Fourth, we could not study direct
indexes of glucose tolerance and insulin sensitivity, because oral glucose tolerance tests and
insulin measurements were not performed in the ENNS study. Fifth, we could not compare
behaviors concerning diet or physical activity as they were collected very differently in the two
studied populations. Another concern is the risk of false positive associations due to multiple
testing. We chose not to perform adjustments for multiple testing because such an approach is
questionable from a methodological standpoint [34], particularly in such exploratory analysis.
Our results show that, as compared to the general population of the same age living in
France, young adults infected with HIV since childhood did not display increased tobacco
consumption, which represent the main modifiable behavioral cardiovascular risk factor. We
can also note that fasting glucose, and LDL-cholesterol did not differ between the two
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populations. The current treatment, care and support for vertically HIV-infected patients may
have contributed to maintain these favourable metabolic parameters. However, young HIV-
infected adults had a higher prevalence of dyslipidemia and android fat distribution, which are
strongly associated with an increased risk of insulin resistance and further cardiometabolic dis-
ease, even in the youngest HIV-infected patients [35]. This supports a close monitoring and
longitudinal screening for the risk of cardiovascular diseases and diabetes in these patients.
Similar attention should be drawn to cognitive dysfunction which has been associated with
central obesity and diabetes in HIV patients [36, 37]. An ongoing long-term study will deter-
mine whether these increased risk factors correlate with alterations of functional cardiovascu-
lar markers in this cohort.
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